Expanding Access to Preventive Chemotherapy for Mobile and Migrant Communities
Official title: A Community Mapping and Participatory Research Protocol for Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations Through Social and Occupational Networks in Nigeria: MISSION Nigeria
Run by Akwa Ibom State University, Ikot Akpaden, Nigeria · NCT07707817 · Data updated 2026-11-12
This project tests whether a modified mass drug administration approach can reach mobile and migrant groups in Nigeria to reduce infections from river blindness, schistosomiasis, intestinal worms, and lymphatic filariasis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 5 Years and up |
| Sex | All |
| Enrollment | 5760 (estimated) |
| Sponsor | Akwa Ibom State University, Ikot Akpaden, Nigeria Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Ondo, Ondo, Taraba and Akwa Ibom) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | July 30, 2027 |
| Study ends | November 30, 2027 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT07707817 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 5-14 or adult heads of households living in mobile or migrant households within the selected Nigerian communities who have missed prior rounds of MDA.
✕Probably not a fit
Participants who are temporary visitors or do not reside in the study communities or who refuse participation may not benefit from the intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an implementation research study conducted in 15 communities across four locations in Nigeria. It uses community mapping and participatory action methods to identify mobile and migrant populations and to tailor distribution of preventive chemotherapy (albendazole, praziquantel, ivermectin) through social and occupational networks. The study examines burden and barriers to access, and tests strategies to expand coverage of mass drug administration among these groups. Data will be collected through biological samples, interviews, surveys, and workshops to inform scalable approaches for reaching marginalized populations. The project involves multiple institutions and aims to inform policy and practice for NTD elimination in mobile populations.
Why it matters
Potential benefit: If successful, the approach could improve coverage of preventive chemotherapy for NTDs among mobile and migrant populations, reducing morbidity and transmission.
How similar studies have gone: Previous implementation efforts have shown that targeted, community-based distribution can improve uptake of preventive chemotherapy in hard-to-reach groups, but results vary by setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants will be eligible for inclusion if they: 1. Are children aged 5-14 years or adult heads of households residing in households identified as belonging to mobile or migrant populations. 2. Reside permanently or semi-permanently within the study communities 3. Have missed one or more previous rounds of onchocerciasis and/or lymphatic filariasis MDA. 4. Are willing to provide the required biological specimens and participate in interviews, surveys, and participatory workshops or discussions as required by the study protocol. 5. Provide informed consent or assent with parental/guardian consent where applicable for minors. Exclusion Criteria: Participants will be excluded if they: 1. Are temporary visitors without meaningful residence in the study communities. 2. Do not belong to the identified mobile or migrant populations targeted by the study. 3. Are unable or unwilling to provide the required biological specimens or participate in study procedures. 4. Decline informed consent or assent, or whose parent or guardian declines consent for participation. 5. Are severely ill or have medical conditions that, in the opinion of study personnel, would make participation unsafe or inappropriate.
Where it's running
-
Recruitment is done at the Household level in selected communities
Ondo, Ondo, Taraba and Akwa Ibom, Nigeria Recruiting
Study contacts
- Principal investigator: Uwem Ekpo, PhD — Akwa Ibom State University
- Study coordinator: Uwem Ekpo, PhD
- Email: uwemekpo@aksu.edu.ng
- Phone: +2348092024306
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Community spread of multiple infectious diseases in Cambodia from a One Health perspective
This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.
-
Better options for treating lymphatic filariasis and other infections in communities
This trial tests whether a three-drug regimen (moxidectin, diethylcarbamazine, and albendazole) can clear lymphatic filariasis, scabies, and strongyloidiasis in people in affected communities, compared with the standard regimen (ivermectin, DEC, and albendazole).
-
Evaluating active schistosomiasis infections in travelers and migrants
This study is trying to find out how many travelers and migrants with chronic schistosomiasis still have active infections by using various tests and evaluations.
-
Using arpraziquantel to treat schistosomiasis in preschool-aged children
This study is testing how well different ways of giving a new child-friendly medicine for schistosomiasis work for preschool-aged kids in Côte d'Ivoire, Kenya, and Uganda.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.